文献速递肾癌与肾肿瘤

美国肾细胞癌的临床分期迁移与生存

Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States.
PubMed 文献 · Eur Urol Oncol · 2018-09-25

该研究基于美国国家癌症数据库2004至2015年262597例肾细胞癌患者,评估临床分期迁移与生存变化。结果显示临床I期诊断比例达70%后趋于稳定,分期迁移似已结束;晚期患者五年总生存改善,全身治疗与生存改善相关(HR 0.811)。

要点

  • 临床I期肾细胞癌诊断比例达70%后稳定,分期迁移似已结束。
  • 局限期肿瘤体积持续缩小,晚期肿瘤比例稳定,仅11%初诊即为远处转移。
  • 近年晚期患者五年总生存改善,全身治疗与生存改善相关(HR 0.811)。

核心结论

  • 临床I期肾细胞癌比例已稳定在70%,提示分期迁移可能已经结束。
  • 局限期肿瘤检出体积持续缩小,而晚期肿瘤保持稳定。
  • 仅11%患者初诊即为远处转移,但近年五年总生存改善,归因于治疗改善而非分期迁移。

研究设计与样本

  • 基于美国国家癌症数据库的流行病学评估,纳入2004至2015年诊断的262597例肾细胞癌患者,覆盖超过1500家机构。

主要发现

  • 临床I期诊断比例达70%(p<0.001),临床III期降至8%(p<0.001)、IV期降至11%(p<0.001),至2007年下降后稳定至2015年。
  • 局限期肿瘤平均大小持续减小:I期平均减小0.22cm,II期平均减小1.24cm(2004至2015年)。
  • 组织学类型与分期呈显著关联。
  • 五年总生存率从67.9%(2004年)提高至72.3%(2010年),获益见于晚期肾细胞癌而非局限期肿瘤。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文述及国家癌症数据库的局限性适用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The rising incidence of renal cell carcinoma (RCC) since the 1980s has been accompanied by stage migration toward early-stage (stage I) cancers. Stage migration drove an apparent increase in survival for RCC since the 1980s, but it is unclear whether it remains a contributor more recently. OBJECTIVE: To determine whether clinical stage migration has persisted and the relative impact of stage migration versus improvements in treatment on survival for RCC. DESIGN, SETTING, AND PARTICIPANTS: An epidemiologic assessment of stage migration and survival for 262 597 patients at diagnosis of RCC (2004-2015) across >1500 facilities in the National Cancer Database. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Proportion of patients over time was assessed by clinical stage at diagnosis via Cochran-Armitage chi-square tests and linear regression. Mortality data were assessed with the Kaplan-Meier method for 5-yr overall survival, Cox proportional hazards regression, and propensity score matching to differentiate the impact of treatment including systemic therapy from stage migration. RESULTS AND LIMITATIONS: Greater diagnosis of clinical stage I disease (70%; p<0.001) was observed, with decreased diagnosis of stage III (8%; p<0.001) and stage IV (11%; p<0.001) up to 2007 followed by stabilization through 2015. Tumor size continues to decrease for localized tumors (mean-0.22cm stage I and-1.24cm stage II, 2004-2015). Histology demonstrated significant associations with stage. Five-year overall survival improved (67.9% [2004] to 72.3% [2010]) with gains in advanced RCC but not localized tumors. Models confirmed improved survival in recent years for stage IV patients. Systemic therapy was associated with improved survival (hazard ratio 0.811 [0.786-0.837], p<0.001). National Cancer Database limitations apply. CONCLUSIONS: The proportion of patients presenting with stage I RCC has stabilized (70%), suggesting that stage migration may have ended. Localized tumors are detected with decreasing size, while advanced cancers have remained stable. Only 11% of patients now present with distant metastatic disease, but 5-yr overall survival is improving in recent years due to improved treatments rather than stage migration. PATIENT SUMMARY: In this study, we found that stage migration toward early-stage cancers has ended for renal cell carcinoma (RCC). However, improved treatment for advanced RCC appears to be responsible for improved survival in recent years.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Patel HD, Gupta M, Joice GA, et al. Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States. Eur Urol Oncol. 2018. PMID: 31277771. doi:10.1016/j.euo.2018.08.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。